← 홈

HER2+ 유방암

465개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 465개
ADCBiologicstaleZheng YabingPhase 2

Ribociclib Oral Tablet (Ribociclib Oral Tablet)

HER2-positive Advanced Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 66.1%임상시험 30상태 ACTIVE
ADCBiologicstaleRochePreclinical

ado-trastuzumab emtansine (Kadcyla, T-DM1, T-DM1 adjuvant)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+1
임상시험 30상태 RECRUITING
ADCBiologicstaleRochePhase 2

ado-trastuzumab emtansine (Kadcyla, T-DM1, T-DM1 and Pertuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 69.3%임상시험 30상태 RECRUITING
AntibodystaleJazz PharmaceuticalsPhase 3

Zanidatamab (Zanidatamab)

HER2-positive Breast Cancer; Breast Cancer · HER2

#HER2#Antibody#Phase3#항체#면역항체+4
효능 ORR 34%임상시험 30상태 RECRUITING
ADCBiologicstaleJiangsu HengRui Medicine Co., L…Phase 2

pyrotinib plus capecitabine (pyrotinib plus capecitabine)

Metastatic Breast Cancer in the Brain · Metastatic Breast Cancer in the Brain

#MetastaticBreastCancerintheBrain#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 30상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 3

Patritumab Deruxtecan (Patritumab Deruxtecan)

Lung Neoplasm Malignant · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 28상태 RECRUITING
ADCBiologicstaleEMD Serono Research & Developme…Phase 2

Tepotinib (Tepotinib)

Non-small Cell Lung Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 54.7%임상시험 28상태 ACTIVE
ADCBiologicstaleZhenzhen LiuPreclinical

Herombopag (Herombopag)

HER2-positive Breast Cancer · HER2

#HER2#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+2
임상시험 27상태 RECRUITING
ADCBiologicstaleAbbViePhase 1

IMGN853 (Mirvetuximab Soravtansine, Mirvetuximab Soravtansine (IMGN853))

Breast Cancer Triple Negative · Breast Cancer Triple Negative

#BreastCancerTripleNegative#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 100%임상시험 27상태 DISCONTINUED
AntibodystaleZhiyong YuPhase 2

Inetetamab (Inetetamab)

Metastatic Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+3
임상시험 26상태 ACTIVE
ADCBiologicstaleGBG Forschungs GmbHPhase 2

Phesgo (Phesgo)

HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 50%임상시험 26상태 RECRUITING
ADCBiologicstaleShanghai Hengrui Pharmaceutical…Phase 2

SHR-A2102 (SHR-A2102)

Advanced Breast Cancer; Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 25상태 RECRUITING
ADCBiologicstaleQuantumLeap Healthcare Collabor…Phase 2

ARV-471 (ARV-471)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 0%임상시험 24상태 RECRUITING
ADCBiologicstaleQuantumLeap Healthcare Collabor…Phase 2

PLX3397 (PLX3397)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 33.3%임상시험 24상태 RECRUITING
ADCBiologicstaleSpectrum Pharmaceuticals, IncPhase 1

Poziotinib (Poziotinib)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 30%임상시험 24상태 DISCONTINUED
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

U3-1402 (U3-1402)

Metastatic Breast Cancer; Advanced Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 24상태 ACTIVE
ADCBiologicstaleByondis B.V.Phase 3

trastuzumab (Herceptin, vic-, (vic-)trastuzumab duocarmazine)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 27.8%임상시험 23상태 ACTIVE
AntibodystaleRegeneronPhase 2

Cemiplimab plus REGN3767 (Cemiplimab plus REGN3767)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 23상태 RECRUITING
ADCBiologicstaleShanghai Henlius BiotechPhase 3

TCbHP (TCbHP)

HER2 + Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 23상태 RECRUITING
ADCBiologicstaleInstitut du Cancer de Montpelli…Phase 1

TDM1 (TDM1)

HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 9.3%임상시험 22상태 ACTIVE

7 / 24 페이지

← 이전다음 →